BPMX - BioPharmX Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
0.3724
-0.0059 (-1.55%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.3783
Open0.0000
Bid0.3000 x 1100
Ask0.3800 x 2900
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume845,460
Market Cap5.283M
Beta (3Y Monthly)0.15
PE Ratio (TTM)N/A
EPS (TTM)-1.5580
Earnings DateJun 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.63
Trade prices are not sourced from all markets
  • What Kind Of Investor Owns Most Of BioPharmX Corporation (NYSEMKT:BPMX)?
    Simply Wall St.

    What Kind Of Investor Owns Most Of BioPharmX Corporation (NYSEMKT:BPMX)?

    Every investor in BioPharmX Corporation (NYSEMKT:BPMX) should be aware of the most powerful shareholder groups...

  • PR Newswire

    BioPharmX Reports Fiscal Second Quarter 2020 Financial Results and Provides Corporate Update

    SAN JOSE, Calif. , Sept. 9, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports ...

  • PR Newswire

    BioPharmX Announces Steven M. Bosacki Joins the Company as Chief Operating Officer

    SAN JOSE, Calif., July 16, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announces the appointment of Steven M. Bosacki, a 20 year pharmaceutical industry veteran, as its Chief Operating Officer. Mr. Bosacki previously served as Senior Vice President and General Counsel under BioPharmX CEO, Dr. David S. Tierney, at Oceana Therapeutics.

  • Did BioPharmX Corporation (NYSEMKT:BPMX) Insiders Sell Shares?
    Simply Wall St.

    Did BioPharmX Corporation (NYSEMKT:BPMX) Insiders Sell Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • PR Newswire

    BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea

    SAN JOSE, Calif., June 25, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced positive results from its Phase 2b clinical trial of BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea. BPX-04, a 1% minocycline gel, successfully met both the primary and secondary endpoints of the trial in demonstrating a statistically significant mean change in the number of facial inflammatory lesions and a two-grade improvement to clear or almost clear on the Investigator's Global Assessment (IGA) scale from baseline to week 12.

  • PR Newswire

    BioPharmX Reports Fiscal First Quarter 2020 Financial Results

    SAN JOSE, Calif. , June 11, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports ...

  • PR Newswire

    BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea

    SAN JOSE, Calif., May 22, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, announced today that the last patient in the Company's Phase 2b clinical trial of BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea, has completed their last clinical visit. "We are pleased to announce this important milestone and look forward to reporting topline results from the study in early July 2019, subject to successful database lock and results validation," said Dr. David S. Tierney, BioPharmX Chief Executive Officer. The randomized, double-blind, vehicle-controlled study enrolled 206 subjects with moderate-to-severe papulopustular rosacea.

  • PR Newswire

    BioPharmX Completes 1-for-25 Reverse Stock Split

    SAN JOSE, Calif., April 26, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announces the completion of the reverse stock split previously announced on April 15, 2019 to regain compliance with certain NYSE American continued listing standards related to the low price per share of the Company's common stock. The reverse stock split became effective at 4:01 pm Eastern Time on April 25, 2019.

  • PR Newswire

    BioPharmX Announces Reverse Stock Split

    SAN JOSE, Calif., April 15, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that its Board of Directors has approved a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective on April 25, 2019 (the "Effective Date"), and the shares will begin trading on the split-adjusted basis on the NYSE American under the Company's existing trading symbol "BPMX" at market open on April 26, 2019. The new CUSIP number following the reverse stock split will be 09072X 309.

  • PR Newswire

    BioPharmX Announces $3.9 Million Offering

    SAN JOSE, Calif., March 21, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 43,645,000 shares of common stock at a price of $0.09 per share in a registered direct offering. Net proceeds of the offering will be used to advance the BioPharmX clinical programs, product development and general corporate purposes. The shares of common stock were offered by BioPharmX pursuant to a shelf registration statement on Form S-3 (File No. 333-229459) which was declared effective by the Securities and Exchange Commission (SEC) on February 13, 2019.

  • ACCESSWIRE

    Watch These Four Healthcare Stocks Set The Pace On Tuesday

    Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.

  • PR Newswire

    BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference

    SAN JOSE, Calif. , March 18, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced ...

  • PR Newswire

    BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results

    SAN JOSE, Calif. , March 14, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports ...

  • Can We See Significant Institutional Ownership On The BioPharmX Corporation (NYSEMKT:BPMX) Share Register?
    Simply Wall St.

    Can We See Significant Institutional Ownership On The BioPharmX Corporation (NYSEMKT:BPMX) Share Register?

    Every investor in BioPharmX Corporation (NYSEMKT:BPMX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend toRead More...

  • PR Newswire

    BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea

    SAN JOSE, Calif., March 4, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has completed enrollment of its Phase 2b clinical trial with BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea. "This is an important milestone for our rosacea program and we look forward to reporting topline results from the study later this year," said David Tierney, BioPharmX CEO.

  • ACCESSWIRE

    These Four Tech Stocks Could Test February Highs

    CORAL GABLES, FL / ACCESSWIRE / February 28, 2019 / The tech stock market has been a hotbed of excitement as a result of companies in the tech industry working to develop innovative new products to revamp the quality of life enjoyed by consumers. Consumers may not be aware of the fiscal happenings of companies working in tech, but they are likely more familiar with the products and services being released to the public. ParcelPal Technology Inc (PTNYF) (PKG), DPW Holdings Inc (NYSE American: DPW),BioPharmx Corporation (NYSE American: BPMX), and DropCar Inc (NASDAQ:DCAR) represent 4 tech stocks on the rise on Thursday.

  • PR Newswire

    BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American

    SAN JOSE, Calif., Feb. 27, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, received a notice on February 25, 2019 from the NYSE American LLC (the "NYSE American") that granted the Company an extension from February 27, 2019 to April 30, 2019 to regain compliance with certain NYSE American continued listing standards related to the low price per share of the Company's common stock.

  • PR Newswire

    BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott

    SAN JOSE, Calif., Feb. 4, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced the appointment of veteran pharmaceutical developer R. Todd Plott, M.D., as an independent director. 16 years of which were spent  working as a research physician with the pharmaceutical industry.

  • GlobeNewswire

    Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX — Future Expectations, Projections Moving into 2019

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE

    Market Rally Extends to Biotech

    HENDERSON, NV / ACCESSWIRE / January 9, 2019 / Markets are rallying in first full market week of 2019 and the biotech sector is responding as many oversold small caps are starting to rebound. We've found ...

  • PR Newswire

    BioPharmX Receives Notice of Noncompliance from NYSE American

    MENLO PARK, Calif., Dec. 20, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, received a notice on December 17, 2018 from the NYSE American LLC (the "NYSE American") that the Company is not in compliance with the stockholders' equity requirements set forth in Section 1003(a)(i) and Section 1003(a)(ii) of the NYSE American Company Guide. The Company reported stockholders' equity of $0.6 million as of October 31, 2018 and net losses in its five most recent fiscal years ended January 31, 2018.  The continued listing standards require listed companies to maintain stockholders' equity of $2.0 million or more if they have reported losses from continuing operations and/or net losses in their three most recent fiscal years.  NYSE Regulation has reviewed the Company's compliance plan and has granted a plan period through September 24, 2019.

  • PR Newswire

    BioPharmX Reports Third Quarter 2019 Financial Results

    MENLO PARK, Calif. , Dec. 6, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports ...

  • Is BioPharmX Corporation’s (NYSEMKT:BPMX) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.

    Is BioPharmX Corporation’s (NYSEMKT:BPMX) Balance Sheet Strong Enough To Weather A Storm?

    BioPharmX Corporation (NYSEMKT:BPMX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is BPMX will Read More...

  • PR Newswire

    BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance

    MENLO PARK, Calif., Nov. 16, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market, announced that on November 1, 2018, NYSE Regulation accepted the Company's plan to regain compliance with the NYSE American LLC ("NYSE American") continued listing standards set forth in Sections 1003(a)(iii) of the NYSE American Company Guide. NYSE Regulation has reviewed the Company's compliance plan and has granted a plan period through September 24, 2019.